Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOMOX-HAIC, Sintilimab, and Bevacizumab in Advanced HCC
NCT06285019Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of raltitrexed in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started Dec 2023; status: recruiting.
02
Drugs
raltitrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06285019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285019.